(Q46896761)

26 December 2017

title

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis (English)

1 reference

26 December 2017

1 reference

1 reference

1 reference

8

Joseph Peuskens

1 reference

26 December 2017

Guillermo Jasso Mosqueda

6

object named as

Guillermo Jasso Mosqueda

1 reference

26 December 2017

Diana De Graeve

1

1 reference

ORCID Public Data File 2021

author name string

Ann Smet

2

1 reference

26 December 2017

Angelika Mehnert

3

1 reference

26 December 2017

Sue Caleo

4

1 reference

26 December 2017

Houda Miadi-Fargier

5

1 reference

26 December 2017

Damien Lecompte

7

1 reference

26 December 2017

publication date

1 January 2005

1 reference

26 December 2017

published in

PharmacoEconomics

1 reference

26 December 2017

volume

23 Suppl 1

1 reference

26 December 2017

page(s)

35-47

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.2165/00019053-200523001-00004

exact match

0 references

cites work

Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Risperidone. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Long-term depot antipsychotics. A risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Guidelines for depot antipsychotic treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Long-acting risperidone: a review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Modelling in economic evaluation: an unavoidable fact of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Olanzapine. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Risperidone versus haloperidol: II. Cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Cost Analysis of the Treatment of Schizophrenia in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200523001-00004

Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group

21 January 2018

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Assessment and treatment selection for "revolving door" inpatients with schizophrenia

1 reference

12 December 2020

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

1 reference

12 December 2020

Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses

1 reference

12 December 2020

Patient compliance with drug therapy in schizophrenia. Economic and clinical issues

1 reference

12 December 2020

Health care expenditure on schizophrenia patients in Belgium

1 reference

12 December 2020

A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium

1 reference

12 December 2020

Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone

1 reference

12 December 2020

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

1 reference

12 December 2020

Prospective study of course of illness in schizophrenia: Part III. Treatment and outcome

1 reference

12 December 2020

The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective

1 reference

12 December 2020

Depot neuroleptic therapy: clinical considerations

1 reference

12 December 2020

The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment

1 reference

12 December 2020

10.2165/00019053-200523001-00004

Identifiers

DOI

0 references

Dimensions Publication ID

1024812666

0 references

1 reference

26 December 2017